Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Study suggests new targets for treating rare genetic disorder and cancer

Study suggests new targets for treating rare genetic disorder and cancer

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

NCI awards 'provocative questions' grants to Jackson lab researchers

NCI awards 'provocative questions' grants to Jackson lab researchers

Study reveals how BTK mutation triggers drug resistance in CLL patients

Study reveals how BTK mutation triggers drug resistance in CLL patients

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Findings may help medical researchers identify effective drug targets for triple negative breast cancer

Findings may help medical researchers identify effective drug targets for triple negative breast cancer

Longer looks: How doctors treat patients; myths about Obamacare; curing cancer

Longer looks: How doctors treat patients; myths about Obamacare; curing cancer

New database allows researchers to match old drugs for new diseases

New database allows researchers to match old drugs for new diseases

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx announces financial results for Q1 2014, provides operational update

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

First Edition: May 16, 2014

First Edition: May 16, 2014

A potential epigenetic 'on-off' switch for cancer

A potential epigenetic 'on-off' switch for cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.